The Medical Letter®

on Drugs and Therapeutics

Volume 60 April 9, 2018



IN THIS ISSUE
Correction p 64

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 60 (Issue 1544) **April 9, 2018**

Correction: Antiplatelet Effects of Diflunisal

In issue 1540 on nonopioid drugs for pain (Med Lett Drugs Ther 2018; 60:24), we said that nonacetylated salicylates such as diflunisal and salsalate do not interfere with platelet aggregation. That is not entirely true for diflunisal. Although low doses (250 mg twice daily) of diflunisal have no effect on platelets and the usual dosage of 500 mg twice daily has a minimal effect that is not likely to have clinical significance, a dosage of 1000 mg twice daily, which is larger than the recommended maximum dosage, may transiently inhibit platelet function (D Green et al. Effects of diflunisal on platelet function and fecal blood loss. Pharmacotherapy 1983; 3(2pt2):65S).



Follow us on Twitter W Like us on Facebook



PRESIDENT: Mark Abramowicz, M.D.; VICE PRESIDENT AND EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; ASSOCIATE EDITORS: Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D.; CONSULTING EDITORS: Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University, Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; F. Estelle R. Simons, M.D., F.R.C.P.C., F.R.S.C., University of Manitoba; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; ASSISTANT MANAGING EDITOR: Liz Donohue

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; SITE LICENSE SALES: Elaine Reaney-Tomaselli; EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; VICE PRESIDENT AND PUBLISHER: Yosef Wissner-Levy

Founded in 1959 by

Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer. The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc. 145 Huguenot St. Ste. 312 New Rochelle, NY 10801-7537 www.medicalletter.org

Get Connected: 🍏 📊

Customer Service: Call: 800-211-2769 or 914-235-0500 Fax: 914-632-1733 E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US): 1 year - \$159; 2 years - \$298; 3 years - \$398. \$65 per year for students, interns, residents, and fellows in the US and Canada Reprints - \$25/article; \$35/issue

Site License Inquiries: E-mail: SubQuote@medicalletter.org Call: 800-211-2769 Special rates available for bulk subscriptions.

Copyright 2018. ISSN 1523-2859

